Skip to content
Research Article Open access CC BY 4.0

Role of Gut Microbiome on Metabolic Disorders

Ifeanyi O. Oshim, Nneka R. Agbakoba, Evelyn U. Urama, Oluwayemisi Odeyemi, Nkechi A. Olise, Godsplan U. John

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 21–35 · Published 1 Jul 2020

10.9734/jamps/2020/v22i530171

Abstract

Microbiome that reside in the human gut are key contributors to host metabolism and are considered potential sources of novel therapeutics in metabolic disorders. This review discusses the role of gut microbiome in the pathogenesis of obesity, type 2 diabetes mellitus (T2DM), chronic kidney disease and cardiovascular disease. Gut microbiome remains quite stable, although changes take place between birth and adulthood due to external influences, such as diet, disease and environment. Understanding these changes is important to predict diseases and develop therapies. In gut heamostasis, Gut microbiome converts high fibres intake into short-chain fatty acids like butyrate, propionate and acetate which normalize intestinal permeability and alter de novo lipogenesis and gluconeogenesis through reduction of free fatty acid production by visceral adipose tissue. This effect contributes to reduce food intake and to improve glucose metabolism. Propionate can also bind to G protein coupled receptors (GPR)-43 expressed on lymphocytes in order to maintain appropriate immune defence. Butyrate activates peroxisome proliferator-activated receptor-γ (PPAR-γ) leading to beta-oxidation and oxygen consumption, a phenomenon contributing to maintain anaerobic condition in the gut lumen. In contrast, diets most especially western diet consisting among others of high fat and high salt content has been reported to cause gut dysbiosis. This alteration of gut microbiome result to chronic bacterial translocation and increased intestinal permeability that can drive a systemic inflammation leading to macrophage influx into visceral adipose tissue, activation of hepatic kuffer cells and insulin resistance in type 2 diabetes. This effect contributes to lower mucus thickness, decrease butyrate and propionate producing bacteria, L-cells secrete less gut peptides, lack of PPAR-γ activation lead to higher oxygen available for the microbiome at the proximity of the mucosa and increases the proliferation of Enterobacteriaceae with commensurate increase in opportunistic pathogens. However, Gut microbiome are major biomarker for early prognosis of diabetes and other metabolic disorders.

Gut microbiome obesity diabetes chronic kidney diseases cardiovascular diseases.

References (74)

  1. 1 Pathogen Recognition and Innate Immunity [DOI]
  2. 2 Diet rapidly and reproducibly alters the human gut microbiome [DOI]
  3. 3 Enterotypes of the human gut microbiome [DOI]
  4. 4 A metagenome-wide association study of gut microbiota in type 2 diabetes [DOI]
  5. 5 Metabolic Endotoxemia Initiates Obesity and Insulin Resistance [DOI]
  6. 6 Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes [DOI]
  7. 7 The gut microbiota shapes intestinal immune responses during health and disease [DOI]
  8. 8 Gut metagenome in European women with normal, impaired and diabetic glucose control [DOI]
  9. 9 Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites [DOI]
  10. 10 Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice [DOI]
  11. 11 Nuclear Receptors and Lipid Physiology: Opening the X-Files [DOI]
  12. 12 Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH [DOI]
  13. 13 Antibiotics in early life alter the murine colonic microbiome and adiposity [DOI]
  14. 14 Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers [DOI]
  15. 15 Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran [DOI]
  16. 16 Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome [DOI]
  17. 17 Treating Clostridium difficile Infection With Fecal Microbiota Transplantation [DOI]
  18. 18 The core gut microbiome, energy balance and obesity [DOI]
  19. 19 Comparison of Body Mass Index, Waist Circumference, and Waist/Hip Ratio in Predicting Incident Diabetes: A Meta-Analysis [DOI]
  20. 20 Worldwide increase in incidence of Type I diabetes - the analysis of the data on published incidence trends [DOI]
  21. 21 The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery [DOI]
  22. 22 Intestinal microbiota in patients with nonalcoholic fatty liver disease [DOI]
  23. 23 High-Fat Diet: Bacteria Interactions Promote Intestinal Inflammation Which Precedes and Correlates with Obesity and Insulin Resistance in Mouse [DOI]
  24. 24 Antibiotics and the gut microbiota [DOI]
  25. 25 The contributory role of gut microbiota in cardiovascular disease [DOI]
  26. 26 Trends in Cardiovascular Complications of Diabetes [DOI]
  27. 27 Infant antibiotic exposures and early-life body mass [DOI]
  28. 28 Association Between the Use of Antibiotics in the First Year of Life and Pediatric Inflammatory Bowel Disease [DOI]
  29. 29 Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk [DOI]
  30. 30 Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both Genetic and Simple Obesity in Children [DOI]
  31. 31 Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients [DOI]
  32. 32 A review of the recent epidemiological data on the worldwide incidence of Type 1 (insulin-dependent) diabetes mellitus [DOI]
  33. 33 C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet [DOI]
  34. 34 Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial [DOI]
  35. 35 Association between caesarean section and childhood obesity: a systematic review and meta‐analysis [DOI]
  36. 36 Clostridium difficile and the microbiota [DOI]
  37. 37 Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk [DOI]
  38. 38 Effects of cyclophosphamide on immune system and gut microbiota in mice [DOI]
  39. 39 Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics [DOI]
  40. 40 The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children [DOI]
  41. 41 Community-Wide Response of the Gut Microbiota to Enteropathogenic Citrobacter rodentium Infection Revealed by Deep Sequencing [DOI]
  42. 42 Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization [DOI]
  43. 43 Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome [DOI]
  44. 44 Change in Visceral Adiposity Independently Predicts a Greater Risk of Developing Type 2 Diabetes Over 10 Years in Japanese Americans [DOI]
  45. 45 RELATION BETWEEN BREAST-FEEDING AND INCIDENCE RATES OF INSULIN-DEPENDENT DIABETES MELLITUS [DOI]
  46. 46 Diagnosis, epidemiology and pathogenesis of diabetes mellitus: An update for psychiatrists [DOI]
  47. 47 The Colon: An Overlooked Site for Therapeutics in Dialysis Patients [DOI]
  48. 48 New Views on Cesarean Section, its Possible Complications and Long-Term Consequences for Children's Health [DOI]
  49. 49 Protective Immunoglobulin A and G Antibodies Bind to Overlapping Intersubunit Epitopes in the Head Domain of Type 1 Reovirus Adhesin σ1 [DOI]
  50. 50 World Diabetes Day: Perspectives on immunotherapy of Type 1 Diabetes [DOI]
  51. 51 From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites [DOI]
  52. 52 Population-level analysis of gut microbiome variation [DOI]
  53. 53 Human gut microbes impact host serum metabolome and insulin sensitivity [DOI]
  54. 54 Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity [DOI]
  55. 55 Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug [DOI]
  56. 56 Antibiotics, birth mode, and diet shape microbiome maturation during early life [DOI]
  57. 57 The microbiome in early life: implications for health outcomes [DOI]
  58. 58 Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer [DOI]
  59. 59 Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by Caesarean section [DOI]
  60. 60 Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes [DOI]
  61. 61 Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease [DOI]
  62. 62 p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease [DOI]
  63. 63 Relationship between Milk Microbiota, Bacterial Load, Macronutrients, and Human Cells during Lactation [DOI]
  64. 64 Universality of human microbial dynamics [DOI]
  65. 65 Preadipocytes Mediate Lipopolysaccharide-Induced Inflammation and Insulin Resistance in Primary Cultures of Newly Differentiated Human Adipocytes [DOI]
  66. 66 Systematic Review of the Human Milk Microbiota [DOI]
  67. 67 Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease [DOI]
  68. 68 The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases [DOI]
  69. 69 Prior Dietary Practices and Connections to a Human Gut Microbial Metacommunity Alter Responses to Diet Interventions [DOI]
  70. 70 The Influence of the Microbiome on Type 1 Diabetes [DOI]
  71. 71 The gut microbiome in human immunodeficiency virus infection [DOI]
  72. 72 Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production [DOI]
  73. 73 Intestinal IgA synthesis: A primitive form of adaptive immunity that regulates microbial communities in the gut [DOI]
  74. 74 Rising risk of type 2 diabetes among inhabitants of Jamnagar, Gujarat: A cross-sectional survey [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

74

Page views

0

PDF downloads

43

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.